Aquestive Therapeutics (NASDAQ:AQST) (NASDAQ: AQST) is a pharmaceutical company specializing in advanced drug delivery platforms designed to improve the safety, efficacy and patient compliance of existing therapies and novel compounds. The company’s proprietary PharmFilm, LiquiFilm, AeroFilm and VosoFilm technologies facilitate oral, buccal and pulmonary administration of drugs via thin polymeric films. These platforms seek to minimize peak-to-trough fluctuations in blood plasma levels, offer rapid onset of action and reduce reliance on traditional oral or injectable dosage forms.
Lead commercial offering Sympazan (diazepam buccal film) was approved by the U.S. Food and Drug Administration in 2020 for the acute treatment of seizure clusters in patients with epilepsy. Aquestive’s development pipeline features Libervant, an improved diazepam buccal film formulation currently under regulatory review, and Qtrypta, a sublingual film candidate for acute migraine management. Additional programs address central nervous system disorders, endocrine therapies and anti-infective treatments, leveraging the versatility of its film-based delivery systems.
Headquartered in Warren, New Jersey, Aquestive integrates research and development, clinical affairs, regulatory strategy and manufacturing under one roof. The company maintains strategic partnerships and licensing agreements to extend its geographic footprint, collaborating with contract manufacturers and specialty pharmaceutical firms to reach markets across North America, Europe and Asia. Aquestive continues to explore new indications and formulations that capitalize on its platform technologies.
Originally founded as MonoSol Rx in 2004 and rebranded as Aquestive in 2012 ahead of its 2015 initial public offering, the company is led by CEO William “Bill” Lewis, who brings over two decades of experience in pharmaceutical development and commercialization. The leadership team comprises executives with deep expertise in drug development, regulatory affairs and commercial operations, positioning Aquestive to advance its innovative delivery solutions and expand its market presence in the years ahead.
